Work

Results of a phase II trial of abiraterone acetate (AA) combined with dutasteride (DUT) for men with metastatic castration resistant prostate cancer (mCRPC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.4_suppl.126

Authors: Rana R. McKay, Lillian Werner, Katherine A. Zukotynski, Liran Domachevsky, Aymen Elfiky, Mark M, Pomerantz, Glenn J. Bubley, Robert B. Montgomery, Philip W. Kantoff, Mary-Ellen Taplin

Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard University, Dana-Farber Brigham Cancer Center, Beth Israel Deaconess Medical Center, University of Washington

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2590235991

Cites:

Cited by:

Related to: 10